Dharti Proteins shuts trading window before Sep 2026 results

Key compliance update for insiders

Dharti Proteins Limited has closed its trading window for equity shares starting October 1, 2026. The restriction applies to Directors, Promoters, Designated Persons, and Specified Connected Persons, as stated in the company’s disclosure. The trading window closure is tied to the release of the company’s unaudited financial results for the quarter and half-year ended September 30, 2026. The company said the closure will remain in effect until 48 hours after those unaudited results are declared. Such windows are commonly used to restrict trading by insiders during periods when unpublished price sensitive information may exist. The filing did not provide a date for the results announcement. It said the board meeting date for considering and approving the results will be communicated in due course.

What the trading window closure means

A trading window closure is an internal compliance control that limits buying or selling of company securities by specified persons. In Dharti Proteins’ case, the restriction begins from October 1, 2026, and continues until two days after the results are declared. The disclosure makes the scope clear by listing Directors, Promoters, Designated Persons, and Specified Connected Persons. The company linked the closure specifically to the unaudited financial results for the quarter and half-year ended September 30, 2026. Investors should note that such announcements do not indicate performance direction on their own. They mainly indicate that a results cycle is approaching and that the company is following its compliance framework. The key pending detail is the board meeting date for approval of results. Dharti Proteins said it will communicate that date later.

AGM corrigendum adds director regularisation item

Separately, Dharti Proteins issued a corrigendum on September 9, 2026 to its Annual General Meeting (AGM) notice scheduled for September 28, 2026. The update added a resolution to regularise the appointment of Mr. Karnik Shasankan Pillai as a Non-Executive Non-Independent Director. The corrigendum stated that the addendum will be treated as an integral part of the original AGM notice. The company also said the added resolution will be included in the remote e-voting facility. This type of corrigendum is typically issued when the company needs to include additional agenda items after the initial notice is circulated. The disclosure provided the director’s DIN as 08529650. The revised agenda included this as Resolution No. 13.

AGM logistics: date, mode, and voting window

The AGM was scheduled for September 28, 2026 at 11:00 am. Dharti Proteins stated that the meeting would be held through Video Conferencing or Other Audio Visual Means (VC/OAVM). The remote e-voting period was communicated as September 25, 2026 (9:00 am) to September 27, 2026 (5:00 pm). The record date was stated as September 21, 2026. The timeline aligns with a process where eligibility to vote is determined first, followed by the e-voting window, and then the AGM itself. These details matter operationally because they define when shareholders can participate and how their votes will be counted. The filing also referenced the AGM purpose entry with AGM date September 28, 2026 and announcement date September 1, 2026. No changes to the stated AGM date or mode were mentioned in the corrigendum excerpt shared.

Convertible loan proposal: up to ₹100 crore

Among the AGM’s financial resolutions, the agenda included approval for an unsecured loan of up to ₹100 crore from Managing Director Jatinbhai Ramanbhai Patel. The disclosure described the facility as a convertible loan, with an option to convert outstanding principal and or interest into equity shares at a later date. The company stated that any such conversion would be subject to SEBI guidelines. The excerpt did not provide the proposed tenure, interest rate, or conversion pricing mechanics. It also did not state whether the company expects to draw the full amount. Still, the inclusion of a conversion option makes the proposal relevant for shareholders because it can have potential equity implications depending on future decisions and approvals. The company’s agenda description focused on the approval sought rather than detailed terms.

Other exchange diary items referenced in the note

The material also included a snapshot of corporate action style entries for Dharti Proteins. It listed an AGM item with announcement date September 1, 2026, along with other calendar references such as Book Closer and a board meeting entry with agenda described as audited result. The excerpt also included a general statement that the company is listed on BSE and NSE and holds regular board meetings to review performance and declare quarterly results. These lines were descriptive and did not add new dated events beyond what was already presented. Importantly, for the Sep 2026 quarter results, Dharti Proteins said the board meeting date for the unaudited results will be communicated later. Investors tracking the company’s results calendar would therefore watch for a separate board meeting intimation. The trading window closure indicates that the results process is underway, but not the exact approval date.

Investor or analyst call intimation for Oct 15, 2026

The note also referenced an exchange intimation of an investor or analyst call scheduled for Thursday, October 15, 2026 (IST). The excerpt did not specify the company name associated with that call in the provided text. It simply stated that the intimation is enclosed. Without additional identifiers, the only confirmed detail is the stated meeting date and that it was an investor or analyst call. Such calls are typically used to discuss performance, strategy, or quarterly developments, but no agenda or dial-in details were included in the excerpt. Readers should treat this as a calendar item unless the full attachment provides further context. The presence of this line alongside other corporate disclosures suggests it was part of a broader exchange feed.

Quick table: Dharti Proteins key dates and items

Market impact: what is known and what is not

The disclosures are primarily compliance and governance updates, not a performance update. Dharti Proteins did not publish revenue, profit, or operational metrics in the provided excerpt. There was also no stock price movement or trading data referenced, so no quantified market reaction can be attributed here. The most financially material item mentioned is the proposal to approve an unsecured loan of up to ₹100 crore, with an option for conversion into equity shares subject to SEBI guidelines. The trading window closure is relevant for insider trading compliance and typically signals an approaching results announcement, but it does not provide a results date. The AGM corrigendum is a governance update, adding a director regularisation resolution and clarifying that it will be part of the e-voting agenda. For investors, the key next confirmed step from the excerpt is the AGM meeting and the shareholder voting window. The next expected corporate communication would be the board meeting date for the unaudited Sep 2026 quarter and half-year results.

Why these filings matter

Taken together, the items show Dharti Proteins moving through standard corporate processes around results, shareholder approvals, and board composition. The trading window closure indicates the company is treating the Sep 30, 2026 results cycle as price sensitive for specified persons until disclosure is made and a 48-hour cooling period passes. The AGM corrigendum demonstrates how companies can formally update meeting agendas while maintaining continuity with the original notice. The director regularisation item, added as Resolution No. 13, also reflects the procedural steps required for board appointments. The ₹100 crore convertible loan resolution is potentially significant because it is a funding item involving the Managing Director and includes a conversion option, which shareholders typically evaluate carefully. However, the excerpt does not include detailed terms, so readers would need the full notice for complete evaluation. The immediate, confirmed timeline items remain the e-voting window and AGM date already specified.

Conclusion

Dharti Proteins’ trading window has been closed since October 1, 2026, and will remain shut until 48 hours after the company declares its unaudited results for the quarter and half-year ended September 30, 2026. Separately, a September 9 corrigendum expanded the September 28 AGM agenda to include director regularisation and reaffirmed the e-voting inclusion. The AGM also includes a proposal to approve an unsecured loan of up to ₹100 crore from the Managing Director with a conversion option subject to SEBI guidelines. The next key update to watch, based on the company’s disclosure, is the announcement of the board meeting date for approving the Sep 2026 quarter and half-year unaudited financial results.